ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Claritas Pharmaceuticals Inc

Claritas Pharmaceuticals Inc (CLAS)

0,025
0,00
(0,00%)
Fermé 13 Janvier 10:00PM

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
0,025
Prix Achat
0,025
Prix Vente
0,035
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
0,025
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

CLAS Dernières nouvelles

Claritas Announces Approval from OTC to Up-List to OTCQB

SAN FRANCISCO, CA and TORONTO, ON, April 07, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") is pleased to...

Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

SAN FRANCISCO, CA and TORONTO, ON, April 05, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") today announced...

Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing

SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has...

Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022

SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that the...

Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners

SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced revised...

Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced that it has...

Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced the Company’s...

Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.

SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to announce it has...

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

SAN FRANCISCO, CA and TORONTO, ON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today outlined the Company’s...

Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it will...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

CLAS - Frequently Asked Questions (FAQ)

What is the current Claritas Pharmaceuticals share price?
The current share price of Claritas Pharmaceuticals is $ 0,025
What is the 1 year trading range for Claritas Pharmaceuticals share price?
Claritas Pharmaceuticals has traded in the range of $ 0,00 to $ 0,00 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
SQGSpackman Equities Group Inc
$ 3,50
(354,55%)
59,45k
KLMKermode Resources Ltd
$ 0,01
(100,00%)
1,42M
GNFIGenifi Inc
$ 0,01
(100,00%)
2k
XBOTRealbotix Corp
$ 0,61
(84,85%)
6,9M
JADEJade Leader Corp
$ 0,04
(60,00%)
177k
AJAAJA Health and Wellness Inc
$ 0,035
(-53,33%)
2k
BYM.HBaymount Incorporated
$ 0,005
(-50,00%)
1 000
ETUE2gold Inc
$ 0,005
(-50,00%)
12,29k
ENTGEntourage Health Corp
$ 0,005
(-50,00%)
16,04k
WWA.PWhitewater Acquisition Corp
$ 0,14
(-48,15%)
5k
XBOTRealbotix Corp
$ 0,61
(84,85%)
6,9M
QNCQuantum Emotion Corp
$ 0,90
(-19,64%)
4,37M
GPUSAlset AI Ventures Inc
$ 0,185
(-11,90%)
4,1M
RHCRoyal Helium Ltd
$ 0,02
(0,00%)
3,47M
THRMTherma Bright Inc
$ 0,04
(-20,00%)
2,71M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock